These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 17921051)

  • 1. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
    Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
    Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
    Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
    Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.
    Oishi M; Chiba K; Malhotra B; Suwa T
    Drug Metab Dispos; 2010 Sep; 38(9):1456-63. PubMed ID: 20530222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects on sleep of anticholinergics used for overactive bladder treatment in healthy volunteers aged > or = 50 years.
    Diefenbach K; Arold G; Wollny A; Schwantes U; Haselmann J; Roots I
    BJU Int; 2005 Feb; 95(3):346-9. PubMed ID: 15679791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years.
    Olshansky B; Ebinger U; Brum J; Egermark M; Viegas A; Rekeda L
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):241-51. PubMed ID: 18832343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK; Glue P; Sweeney K; Anziano R; Mancuso J; Wicker P
    Clin Pharmacol Ther; 2007 Mar; 81(3):377-85. PubMed ID: 17339867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
    Malhotra B; Darsey E; Crownover P; Fang J; Glue P
    Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tolterodine on gastrointestinal transit and bowel habits in healthy subjects.
    Bharucha AE; Seide B; Guan Z; Andrews CN; Zinsmeister AR
    Neurogastroenterol Motil; 2008 Jun; 20(6):643-8. PubMed ID: 18312543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome.
    Tseng LH; Wang AC; Chang YL; Soong YK; Lloyd LK; Ko YJ
    Neurourol Urodyn; 2009; 28(1):47-51. PubMed ID: 19089890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolterodine for the treatment of overactive bladder.
    Salvatore S; Serati M; Bolis P
    Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
    Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
    Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tolterodine on the anticoagulant actions and pharmacokinetics of single-dose warfarin in healthy volunteers.
    Rahimy M; Hallén B; Narang P
    Arzneimittelforschung; 2002; 52(12):890-5. PubMed ID: 12572529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity.
    Brynne N; Stahl MM; Hallén B; Edlund PO; Palmér L; Höglund P; Gabrielsson J
    Int J Clin Pharmacol Ther; 1997 Jul; 35(7):287-95. PubMed ID: 9247842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
    Olsson B; Szamosi J
    Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of muscarinic receptor binding and inhibition of salivation after oral administration of tolterodine in mice.
    Oki T; Maruyama S; Takagi Y; Yamamura HI; Yamada S
    Eur J Pharmacol; 2006 Jan; 529(1-3):157-63. PubMed ID: 16316647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals.
    Jiang F; Yeo CW; Lee SS; Oh MK; Ghim JL; Shon JH; Kim HS; Kim EY; Kim DH; Shin JG
    Pharmacogenet Genomics; 2013 Mar; 23(3):175-9. PubMed ID: 23292115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular side-effects of tolterodine and oxybutynin, a single-blind prospective randomized trial.
    Altan-Yaycioglu R; Yaycioglu O; Aydin Akova Y; Guvel S; Ozkardes H
    Br J Clin Pharmacol; 2005 May; 59(5):588-92. PubMed ID: 15842558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.